10x Genomics (TXG) Announces Preliminary Fourth Quarter and Full Year 2023 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/10/2026
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil prices jump after Trump threatens to hit Iran 'very hard'
- Oracle reports earnings today: Analysts say this metric could 'catalyze higher multiples'
- UBS sees generational semiconductor boom, highlights stock winners
- Hut 8 Mining Corp. (HUT) PT Raised to $55 at KBW As Management Delivers
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Micron to deliver 'another strong quarter', Goldman says
- Supermicro plans $7 billion financing to fund AI server orders
- UK's Ofcom requires tech firms to create crisis response plans
10x Genomics Announces Preliminary Fourth Quarter and Full Year 2023 Results
January 8, 2024 9:00 AM ESTPLEASANTON, Calif., Jan. 8, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced preliminary, unaudited select results for the fourth quarter and full year ended December 31, 2023.
